


North Carolina Statistics

PCSK9 Inhibitors



About PCSK9 Inhibitors

PCSK9 inhibitors are designed for patients with extremely high LDL, or “bad,” cholesterol. The drugs are approved by the Food and Drug Administration to treat:

- **Heterozygous familial hypercholesterolemia**, an inherited condition that causes high levels of LDL cholesterol
- **Clinical atherosclerotic cardiovascular disease**, such as heart attacks or strokes.

Analysis of Health Plan Coverage & Access

A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in North Carolina from January 2017 through December 2017.

Key North Carolina Findings



Rejection Rate:

29%



Appeals Rate:

23%



Final Rejections:

2,097

Of health plans that received at least 100 claims for PCSK9 inhibitors, the following had **the highest rates of rejections:**

- Express Scripts **58%**
- NC Teachers & State Employees **44%**
- Tricare Military Health SVS SYC **55%**
- Medicaid **40%**

The following had **the lowest rates of rejection:**

- Aetna **13%**
- Humana Health Plan **11%**



The following table details claims data for the North Carolina managed care organizations that received at least 100 claims for PCSK9 inhibitors.

Managed Care Organization	Rejection %	Total Claims	Rejections
Express Scripts	58%	176	102
Tricare Military Health SVC SYS	55%	173	95
North Carolina Teachers & State Employees	44%	523	232
Medicaid	40%	179	71
BCBS NC	35%	1018	359
United Health Group	34%	966	324
CVS Health	30%	650	192
Cigna Healthcare	16%	298	49
Aetna	13%	765	100
Humana Health Plan	11%	1526	163

Data source: National data supplier; Medicare, Medicaid, Medicaid managed care, and commercial plans; January-December 2017.



The Institute for Patient Access is a physician led nonprofit 501(c)(3) research organization promoting the benefits of the physician-patient relationship in the provision of quality healthcare.

